Analyst Reco. Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
55.05 ^USD	+0.07%		-7.97%	-17.08%

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI

Analyst Reco.

01-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-07	Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating	MT
12-11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
11-19	RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
11-12	Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $45 From $29, Keeps Equalweight Rating	MT
22/10/25	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $61 From $38, Keeps Buy Rating	MT
08/10/25	RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk	MT
08/08/25	RBC Trims Price Target on Arrowhead Pharmaceuticals to $38 From $40, Keeps Outperform, Speculative Risk	MT
14/05/25	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating	MT
13/05/25	RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating	MT
14/02/25	B. Riley Adjusts Price Target on Arrowhead Pharmaceuticals to $38 From $51, Keeps Buy Rating	MT
12/12/24	B. Riley Lowers Price Target on Arrowhead Pharmaceuticals to $51 From $55, Keeps Buy Rating	MT
03/12/24	HC Wainwright Raises Price Target on Arrowhead Pharmaceuticals to $80 From $60, Keeps Buy Rating	MT
27/11/24	Analyst recommendations: Nvidia, Workday, Doordash, Nutanix, T-Mobile...
22/08/24	Analyst recommendations: Estee Lauder, Sentinelone, Snowflake, Wolfspeed, Admiral...
09/08/24	Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour...
23/07/24	Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...
05/07/24	HC Wainwright Cuts Price Target on Arrowhead Pharmaceuticals to $60 From $90, Keeps Buy Rating	MT
10/05/24	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	MT
08/02/24	B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	MT
07/02/24	UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	MT
04/12/23	BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target	MT
04/12/23	B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating	MT
30/11/23	Morgan Stanley Cuts Price Target on Arrowhead Pharmaceuticals to $37 From $40, Maintains Equal-Weight Rating	MT